We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Multiplex Diagnostic Test Identifies Eighteen Common Respiratory Pathogens

By Biotechdaily staff writers
Posted on 25 Sep 2007
A multiplex-formatted diagnostic test can identify the most common viruses and bacteria that cause respiratory infections in a single reaction tube.

Eleven different respiratory RNA viruses, two DNA viruses, and five pneumonia bacteria can be identified from samples including nasopharyngeal aspirates, nasopharyngeal swabs, and bronchoalveolar lavage.

Traditional tests, such as viral culture and Ag-Ab test, are laborious, time-consuming, and relatively expensive. More...
By enabling healthcare personnel to test for 18 different pathogens for a cost comparable to testing a single pathogen, the Seeplex 18-plex respiratory test changes the system of a ‘single pathogen, single test' testing regime and avoids the high false-positive/negative results associated with conventional multiplexing. The Seeplex 18-plex respiratory test performs multiplexing without cross-reactivity and achieves rapid test results at a minimal cost per test.

The microorganisms detected by the Seeplex test are influenza A virus; influenza B virus; human respiratory syncytial virus A; human respiratory syncytial virus B; human parainfluenzae virus 1; human parainfluenzae virus 2; human parainfluenzae virus 3; human Coronavirus 229E/Nl63; human Coronavirus OC43/HKU1; human Rhinovirus; human Enterovirus; human adenovirus; human Bocavirus; Legionella pneumophila; Streptococcus pneumoniae; Chlamydophila pneumoniae; Haemophilus influenzae; and Mycoplasma pneumoniae.

Developed by Seegene (Rockville, MD, USA), the Seeplex test is based on multiplexing polymerase chain reaction (PCR) technology. It enables healthcare personnel to rapidly determine whether a patient's respiratory ailment is caused by a virus or bacteria, and subsequently prescribe the best course of treatment whether an antibiotic, antiviral, or bed rest.

"Our new 18-plex Respiratory Test is what the clinical healthcare industry has been asking for--the ability to routinely test for a wide spectrum of respiratory pathogens in a single test, at the price of a single pathogen test,” stated Jong-Yoon Chun, founder and CEO, Seegene. "Like our other commercially available tests, notably the recently introduced 18-plex test for human Papillomaviruses, our new respiratory test is simply performed with one multiplex PCR in a single tube and capillary electrophoresis for automated detection of pathogens. These tests use Seegene's DPO [Dual Priming Oligo] primer system, ensuring test reproducibility, specificity, and sensitivity.


Related Links:
Seegene

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.